Beneath the Surface: Moving Beyond Symptomatic Control in Obstructive Hypertrophic Cardiomyopathy


Theodore Abraham, MD, FACC
Meyer Friedman Distinguished Professor of Medicine
Co-Director, University of California at San Francisco HCM Center of Excellence San Francisco, CA
Theodore Abraham, MD, FACC

Dr. Abraham is the Meyer Friedman Distinguished Professor of Medicine and Co-Director of the Hypertrophic Cardiomyopathy Center of Excellence at University of California at San Francisco. He is a board- certified cardiologist who is recognized for his expertise and contributions in Hypertrophic Cardiomyopathy and Advanced Echocardiography. He has had an HCM- centered clinical practice for the last 19 years across 3 institutions starting at the Mayo Clinic Rochester, Johns Hopkins and now at UCSF. Previously he served as the Founder- Director of the Johns Hopkins HCM Center of Excellence. His particular clinical interest is in the management of complex obstructive HCM and the use of advanced imaging in the diagnosis and monitoring of HCM patients. His clinical research program has been a leading site for clinical trials for emerging drug therapies and he serves on the steering and/or publications committees for some of these trials. He has over 150 peer reviewed publications focused on HCM, computational flow dynamics and deep learning, and has had continuous NIH and other research funding for over 20 years. He received the 2019 Richard Popp Teaching and Mentorship Award from the American Society of Echocardiography. He served or serves on the editorial boards of the JACC, JACC Cardiovascular Imaging, JASE and Circulation Imaging.

Steve R. Ommen, MD, FACC, FAHA
Professor of Medicine, Mayo Clinic
Director, Mayo Hypertrophic Cardiomyopathy Clinic Rochester, MN
Steve R. Ommen, MD, FACC, FAHA

Dr. Steve R. Ommen is a Professor of Medicine at Mayo Clinic College of Medicine and a Consultant in the Department of Cardiovascular Medicine. He serves as the Director of the Mayo Hypertrophic Cardiomyopathy Clinic, the largest and longest-standing dedicated HCM Center in the world. Mayo’s HCM clinic is recognized as a leader in clinical outcomes, research, and patient education. Dr. Ommen is also Co-director of the Structural Heart Disease program, Medical Director for AskMayoExpert, and Medical Director of the Center for Connected Care.

Dr. Ommen specializes in caring for patients with structural heart disease with a special emphasis on valvular heart disease and hypertrophic cardiomyopathy (HCM). He directs Mayo Clinic’s Hypertrophic Cardiomyopathy program, which is the world’s largest and longest standing program in this disease. He is a requested speaker globally and helped write international guidelines on the appropriate management of patients with HCM.

Dr. Ommen leads Mayo Clinic’s telemedicine team, a critical component in Mayo Clinic’s strategy to provide comprehensive care with a seamless patient experience. He oversees the development of products, services, and systems that bring health care to patients where they need it.

Additionally, he is active in advocating for the advancement of connected care through discussions and presentations at regional, state, and national levels so that these advancements in health care delivery can be made available to people and patients more broadly.

Dr. Ommen has earned many awards throughout his career including the Outstanding Achievement Award in Clinical Cardiology, the Mayo Award of Individual Excellence, the Mayo Award for Team Excellence, the Excellence in Teaching Recognition for Mayo Clinic College of Medicine, and the Outstanding Course Director Award from the Mayo School of Continuing Medical Education. He has been recognized as one of the top 15 Digital Health care Executives.

Dr. Ommen received his Bachelor of Science degree in Biomedical Engineering from Northwestern University. His undergraduate medical education, Internal Medicine Residency and Cardiovascular Diseases Fellowship were all completed at Mayo Clinic, Rochester, Minnesota.

Carolyn Yung Ho, MD
Medical Director, Cardiovascular Genetics Center
Cardiovascular Division, Brigham and Women's Hospital Harvard Medical School Boston, MA
Carolyn Yung Ho, MD

Carolyn Ho is an Associate Professor of Medicine at Harvard Medical School and Medical Director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital. She obtained her undergraduate degree from Yale University and her medical degree from Harvard Medical School. Dr. Ho trained at Brigham and Women’s Hospital for both Internal Medicine residency and Cardiology fellowship before joining the staff of the Cardiovascular Division in 2001.

Dr. Ho’s research focuses on characterizing early phenotypes of sarcomere mutations in inherited cardiomyopathies, leading a large, multicenter registry of genetic cardiomyopathies, and developing clinical trials to diminish the progression of hypertrophic cardiomyopathy. The overall goal is to use genetic/mechanistic insights, careful clinical study, and collaboration to improve the care of patients and families with genetic heart disease.

Statement of Need

Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disease, with a highly variable phenotypic expression that ranges from no symptoms to drug-refractory heart failure. HCM is a lifelong condition that can worsen over time and is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Patients may go years without a diagnosis despite being symptomatic, putting them at increased risk for atrial fibrillation, stroke, heart failure, and sudden cardiac death.

To provide the best quality of care and achieve optimal outcomes, it is critical for clinicians to properly screen appropriate patients and determine the etiology of symptoms, which are often non-specific. Genetic testing can help determine if the hypertrophy is associated with mutations in one of several sarcomeric genes which encode components of the contractile apparatus of the heart.

In this CME Outfitters OnDemand symposium from Heart Rhythm 2022, three experts in HCM explore the latest strategies and updates in HCM diagnosis and management, including progress with disease-specific treatments that target cardiac myosin.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Apply current, evidence-based diagnostic and treatment strategies to the care of patients with HCM.
  • Assess the chemomechanical cycle of cardiac myosin in HCM and the impact of myosin inhibition on disease factors.
  • Evaluate study results of disease-specific treatments targeting cardiac myosin in HCM.

Financial Support

Supported by an educational grant from Bristol Myers Squibb.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in cardiology and electrophysiology

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hour.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-21-062-H02-P

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations. [Hard return + divider]

Dr. Abraham reports no financial relationships.

Dr. Ommen reports no financial relationships.

Dr. Ho reports the following financial relationships: Advisory Board: Bristol Myers Squibb. Consultant: Tenaya Therapeutics. Research: Pfizer Inc.

  • Jeffrey Helfand, DO (peer reviewer)
  • Warren Beckman (planning committee)
  • Evan Luberger (planning committee)
  • Susan H Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)
  • Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.


Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).



Beneath the Surface: Moving Beyond Symptomatic Control in Obstructive Hypertrophic Cardiomyopathy
Event Date: 05/04/2022